FGFR4 and cancer: In the case of Filgotinib (BLU554), which is closely related to BLU9931, FGFR4 V550L mutations caused resistance to the drug in a clinical trial for hepatic cancer [38], clearly implicating FGFR4 as a driver of this cancer and V550L mutations as gate-keepers for the drug.